UroGen Pharma
URGNApprovedUroGen Pharma is a biopharmaceutical company pioneering novel treatments for uro-oncology, leveraging its proprietary RTGel™ technology platform to enable non-surgical, organ-sparing therapies. The company achieved a significant milestone with the FDA approval and commercialization of JELMYTO® for LG-UTUC, establishing a new standard of care. UroGen is advancing a pipeline of additional candidates, including UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), and is publicly traded on the NASDAQ. Its mission is to transform patient care by providing alternatives to invasive surgeries.
URGN · Stock Price
Historical price data
AI Company Overview
UroGen Pharma is a biopharmaceutical company pioneering novel treatments for uro-oncology, leveraging its proprietary RTGel™ technology platform to enable non-surgical, organ-sparing therapies. The company achieved a significant milestone with the FDA approval and commercialization of JELMYTO® for LG-UTUC, establishing a new standard of care. UroGen is advancing a pipeline of additional candidates, including UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), and is publicly traded on the NASDAQ. Its mission is to transform patient care by providing alternatives to invasive surgeries.
Technology Platform
RTGel™ (Reverse Thermal Gel) is a proprietary hydrogel platform that is liquid at cold temperatures and forms a semi-solid gel at body temperature, enabling sustained, local delivery of therapeutics to urothelial tissue.
Pipeline
14| Drug | Indication | Stage | Watch |
|---|---|---|---|
| UGN-104 | Upper Urinary Tract Urothelial Carcinoma | Phase 3 | |
| UGN-102 | Bladder Cancer | Phase 3 | |
| UGN-101 instillations | Carcinoma, Transitional Cell | Phase 3 | |
| UGN-102 | Bladder Cancer | Phase 3 | |
| UGN-102 | Bladder Cancer | Phase 3 |
Funding History
4FDA Approved Drugs
2Opportunities
Risk Factors
Competitive Landscape
In LG-UTUC, JELMYTO® is first-in-class with limited direct competition. In the potential LG-IR-NMIBC market, UGN-102 would compete against generic intravesical chemotherapies and surgical TURBT, differentiating itself through its sustained-release formulation and potential to serve as a primary non-surgical treatment.